Press Releases

December 20, 2016
REVOLUTION Medicines Raises Additional $25 Million in Series A Financing
December 13, 2016
REVOLUTION Medicines Names Distinguished Cancer Scientists and Drug Hunters to Senior Advisory Roles
June 14, 2016
REVOLUTION Medicines Names Academic Co-Founder, Michael Fischbach, Ph.D., and Senior Advisor, Eric Gordon, Ph.D.
September 30, 2015
FierceBiotech Names Revolution Medicines as a “Fierce 15” Biotech Company of 2015
June 1, 2015
Rationally Designed Antifungal Compounds that Evade Resistance Reported in Nature Chemical Biology by Scientific Founder of REVOLUTION Medicines
April 9, 2015
REVOLUTION Medicines Appoints Pharmaceutical Commercial Executive Elizabeth McKee Anderson to Board of Directors
March 12, 2015
Major Advances in Synthetic Chemistry Reported in Science by Founding Scientist of REVOLUTION Medicines
March 5, 2015
REVOLUTION Medicines Expands Executive Leadership Team
February 4, 2015
Third Rock Ventures Launches REVOLUTION Medicines with $45 Million Series A to Redesign Evolution’s Products to Treat Serious Diseases